Professional development Vacancies

On amending the instructions for medical use of medicinal products containing warfarin (warfarin)

29.10.2021 1412 views

PRAC reviewed cumulative data from spontaneous case reports, clinical studies and literature on the risk of anticoagulant-related nephropathy in patients who received warfarin.

PRAC agreed that all marketing authorization holders of medicinal products containing warfarin must within two months of the publication of the PRAC recommendation amend the package leaflets.

Amendments to be included in the relevant sections of the package insert (new text underlined in bold, deleted text struck through).

Registration certificate holders must also provide, in the next Periodic Safety Update Report (PSUR), a literature review on anticoagulant-related nephropathy, namely with warfarin, with particular emphasis on the potential increase in mortality and decline in renal function as a consequence of anticoagulant-related nephropathy. The review should address any new published information on possible risk factors for the development of anticoagulant nephropathy from warfarin treatment.

“Special precautions for use” section

Use in patients with altered glomerular function Anticoagulant-related nephropathy

In patients with altered glomerular integrity or a history of kidney disease, acute kidney injury may occur, possibly in connection with episodes of excessive anticoagulation and hematuria. Several cases have been reported in patients who had no prior history of kidney disease. Close monitoring, including assessment of renal function, is recommended for patients with a supratherapeutic International Normalized Ratio (INR) and hematuria (including microscopic).

“Adverse reactions” section

Renal and urinary disorders

Anticoagulant nephropathy (see section “Special precautions for use”) with the frequency “Unknown”

Перелік лікарських засобів, що містять warfarin і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 23.10.2021)

To analyze the published information, the applicant must use the original text available at the link: